证券代码：600557 证券简称：康缘药业 公告编号：2025-025 江苏康缘药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）董事会于近日收到公司董 事长肖伟先生提交的书面辞职报告。肖伟先生因个人原因，申请辞去公司第八届 董事会董事长职务，辞去上述职务后，肖伟先生仍将继续担任公司第八届董事会 董事、战略委员会主任委员、审计委员会委员职务。 二、董事长离任对公司的影响 根据《公司法》和《公司章程》的有关规定，肖伟先生的辞职未导致公司董 事会成员低于法定最低人数，其辞职不会影响公司董事会的正常运行，辞职报告 自送达公司董事会之日起生效，公司将尽快完成董事长补选工作。 关于董事长离任的公告 一、董事长提前离任的基本情况 是否存在 | | | | | | | 是否继续在上 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 原定任期 | | 离任 | | | 未履行 ...

证券代码：600557 证券简称：康缘药业 公告编号：2025-025 江苏康缘药业股份有限公司 一、董事长提前离任的基本情况 二、董事长离任对公司的影响 根据《公司法》和《公司章程》的有关规定，肖伟先生的辞职未导致公司董 事会成员低于法定最低人数，其辞职不会影响公司董事会的正常运行，辞职报告 自送达公司董事会之日起生效，公司将尽快完成董事长补选工作。 肖伟先生是公司创始人和实际控制人，自 2000 年 11 月起担任公司董事长， 在公司拥有极高的威望，是公司战略和创新的引领者。在任职期间，肖伟先生恪 尽职守、勤勉尽责，为公司发展倾注了全部心血，推动公司由传统中药企业向现 代化、智能化转型，成功带领公司在上海证券交易所主板上市并不断发展壮大， 在精准把握公司战略方向、推动公司持续、稳健发展以及积极承担社会责任等方 面做出了不可磨灭的贡献，赢得了社会各界的高度赞誉。 公司董事会对肖伟先生为公司发展作出的杰出贡献表示崇高敬意和衷心感 谢！ 特此公告。 关于董事长离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药 ...

康缘药业（600557）公告，公司董事会于近日收到董事长肖伟的书面辞职报告。肖伟因个人原因辞去公 司第八届董事会董事长职务，但仍将继续担任公司董事、战略委员会主任委员、审计委员会委员职务。 辞职报告自送达公司董事会之日起生效，公司将尽快完成董事长补选工作。肖伟自2000年11月起担任公 司董事长，是公司创始人和实际控制人，在公司战略和创新发展方面做出了重要贡献。 ...

Investment Rating - The investment rating for the biopharmaceutical industry is "Positive" (maintained) [2] Core Insights - The GLP-1RA class of drugs, represented by Semaglutide and Tirzepatide, is rapidly expanding, creating a multi-billion dollar market opportunity. By 2031, global sales of GLP-1RA drugs are expected to exceed $150 billion, with significant growth anticipated in the weight loss market post-2025 [6][23] - Major multinational corporations (MNCs) are accelerating their entry into the weight loss and diabetes management market, with frequent high-value business development (BD) transactions. Notable acquisitions include Roche's $3.1 billion purchase of Carmot Therapeutics and Merck's acquisition of Hanmi Pharmaceutical's oral GLP-1 small molecule [25][28] - The development of oral and ultra-long-acting products is expected to enhance patient compliance, with ongoing research into both small molecule and peptide oral drugs. Companies like Eli Lilly and Novo Nordisk are leading in this area, with several domestic firms also showing strong potential for international expansion [30] Summary by Sections 1. MNC Accelerating Layout in Weight Loss and Diabetes Management - GLP-1RA drugs are experiencing rapid growth, with Semaglutide and Tirzepatide leading the market. In 2024, Semaglutide's global sales are projected to be approximately $29.2 billion, a year-on-year increase of about 38%, while Tirzepatide's sales are expected to reach $16.5 billion, growing by approximately 208% [16][17] - The market is currently dominated by Novo Nordisk and Eli Lilly, which together hold nearly 97% market share, indicating a duopoly in the sector [23][24] 2. Enhancing Patient Compliance through Oral and Ultra-Long-Acting Products - The development of oral GLP-1RA drugs is seen as a promising avenue to improve patient adherence, with ongoing research into both small molecule and peptide formulations. Companies like Eli Lilly and Novo Nordisk are at the forefront of this innovation [30] - Ultra-long-acting formulations are also being developed, significantly extending dosing intervals and simplifying treatment regimens, which is expected to further enhance patient compliance [7][30] 3. Multi-Target Drug Development and Combination Therapies - Multi-target weight loss drugs are being developed to overcome the limitations of single-target therapies, aiming to activate or inhibit multiple metabolic receptors for improved efficacy. Key targets include GIPR, GCGR, and AMYR [8][29] - Combination therapies that integrate special targets are anticipated to set new standards in weight loss treatment, focusing on fat reduction while preserving lean body mass [8][29] 4. Investment Recommendations - The report recommends several companies as potential investment opportunities, including Innovent Biologics, East China Pharmaceutical, and Boehringer Ingelheim, which are well-positioned in the weight loss and diabetes management sectors. Beneficiary companies include Heng Rui Medicine, Shijiazhuang Pharmaceutical Group, and others [9]

Investment Rating - The report maintains a "Strong Buy" investment rating for the company [3][7]. Core Insights - The company is undergoing a sales transformation focused on academic marketing, which, despite short-term performance pressures, is expected to enhance the overall marketing system [7]. - The value of the company's R&D pipeline is becoming evident, with multiple products in traditional Chinese medicine, chemical drugs, and biological drugs entering clinical trials or receiving approvals [7]. - The acquisition of China New Medicine in 2024 enhances the company's R&D capabilities in the biopharmaceutical sector, particularly in metabolic and neurological diseases [7]. Financial Data and Valuation - Total revenue for 2023 is reported at 4,868 million, with a projected decline to 3,898 million in 2024, followed by a recovery to 4,314 million in 2025 [2][10]. - The net profit attributable to the parent company is expected to decline from 537 million in 2023 to 392 million in 2024, before rebounding to 443 million in 2025 [8][10]. - The company’s R&D expenditure is projected to be 6.38 billion in 2024, representing a 16.4% R&D expense ratio, which is among the highest in the traditional Chinese medicine industry [7]. Sales and Marketing Strategy - The company has initiated an academic marketing model transformation, which includes the "Doctor Pan Project" aimed at enhancing compliance in sales operations [7]. - A refined sales strategy is being implemented, focusing on product characteristics and therapeutic areas, with a notable reduction in sales expenses by 20.7% in 2024 [7]. R&D Pipeline - As of Q1 2025, the company has several products in various stages of development, including 4 innovative traditional Chinese medicine drugs and 4 chemical drugs in clinical trials [7]. - The company has received clinical approval for two of its self-developed biological drugs in 2024, targeting multiple myeloma and psoriasis [7]. Future Projections - The company is expected to achieve net profits of 4.4 billion, 5.3 billion, and 6.3 billion for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 13.0%, 20.2%, and 18.4% [7][8].

Market Overview - The Shanghai Composite Index rose by 0.52% on June 11, with 28 out of 33 sectors experiencing gains, led by the non-ferrous metals and agriculture sectors, which increased by 2.21% and 2.02% respectively [1] - The pharmaceutical and biotechnology sector was the biggest loser, declining by 0.41% [1] Capital Flow Analysis - The net inflow of capital in the two markets was 1.506 billion yuan, with 14 sectors seeing net inflows [1] - The non-bank financial sector had the largest net inflow of 4.469 billion yuan, rising by 1.90%, followed by the automotive sector with a net inflow of 2.750 billion yuan and a daily increase of 1.70% [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector saw a net outflow of 2.629 billion yuan, with 475 stocks in the sector; 157 stocks rose while 306 fell [2] - The top three stocks with the highest net inflow were Kangyuan Pharmaceutical (2.42 billion yuan), Rundu Co., Ltd. (1.56 billion yuan), and Baiyang Pharmaceutical (840.855 million yuan) [2] - The stocks with the largest net outflows included Hengrui Medicine (1.53 billion yuan), Yong'an Pharmaceutical (1.36 billion yuan), and Kailai Pharmaceutical (1.27 billion yuan) [2] Top Gainers in Pharmaceutical Sector - Kangyuan Pharmaceutical: +9.97%, turnover rate 8.65%, net inflow 241.8664 million yuan [4] - Rundu Co., Ltd.: +9.98%, turnover rate 14.71%, net inflow 155.7670 million yuan [4] - Baiyang Pharmaceutical: +10.33%, turnover rate 8.13%, net inflow 84.0855 million yuan [4] Top Losers in Pharmaceutical Sector - Hengrui Medicine: -0.76%, turnover rate 0.59%, net outflow -153.0498 million yuan [4] - Yong'an Pharmaceutical: -8.87%, turnover rate 24.11%, net outflow -135.7947 million yuan [4] - Kailai Pharmaceutical: -2.35%, turnover rate 1.71%, net outflow -127.0972 million yuan [4]

证券简称：康缘药业 证券代码：600557 公告编号：2025-024 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）分别于 2025 年 4 月 2 日、 2025 年 4 月 24 日召开第八届董事会第十六次会议、2024 年年度股东会，审议通过 了《关于修改<公司章程>的议案》。公司于 2025 年 5 月 30 日召开第八届董事会第 十九次临时会议，审议通过了《关于变更法定代表人的议案》。具体内容详见公司 在《中国证券报》《上海证券报》《证券日报》《证券时报》及上海证券交易所网站 www.sse.com.cn 披露的《第八届董事会第十六次会议决议公告》（公告编号：2025- 007）、《关于修改<公司章程>的公告》（公告编号：2025-013）、《2024 年年度股东会 决议公告》（公告编号：2025-016）、《第八届董事会第十九次临时会议决议公告》 （公告编号：2025-022）。 近日，公司已完成注册资本、法定代表人工商变更登记及修订后的《公司章程》 等备案手续，并取 ...

Core Viewpoint - Jiangsu Kangyuan Pharmaceutical Co., Ltd. has completed the registration of changes in registered capital and legal representative, and has obtained a new business license following the amendments to its Articles of Association [1][2]. Group 1: Company Changes - The registered capital has been changed from RMB 581,797,452 to RMB 566,158,806 [2]. - The legal representative has been changed from Xiao Wei to Gao Haixin [2]. - The company has completed the necessary registration and filing procedures with the Lianyungang Market Supervision Administration [2]. Group 2: Business License Information - The new business license details include: - Name: Jiangsu Kangyuan Pharmaceutical Co., Ltd. - Unified Social Credit Code: 91320700138997640W - Type: Joint-stock company (listed) - Address: Lianyungang Economic and Technological Development Zone, Jiangning Industrial City - Legal Representative: Gao Haixin - Registered Capital: RMB 566,158,806 - Establishment Date: May 8, 1996 [2]. Group 3: Business Scope - The business scope includes the production of traditional Chinese medicine, chemical drugs, biological drugs, natural drug products, and food, among others [2]. - The company is also involved in the import and export of various goods and technologies, subject to national regulations [2]. - Special medical purpose formula food production is a licensed project that requires approval from relevant authorities [2].

证券简称：康缘药业 证券代码：600557 公告编号：2025-024 江苏康缘药业股份有限公司 关于完成工商变更登记并换发营业执照的公告 统一社会信用代码：91320700138997640W 类型：股份有限公司（上市） 住所：连云港经济技术开发区江宁工业城 法定代表人：高海鑫 注册资本：56615.8806 万元整 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）分别于 2025 年 4 月 2 日、 2025 年 4 月 24 日召开第八届董事会第十六次会议、2024 年年度股东会，审议通过 了《关于修改<公司章程>的议案》。公司于 2025 年 5 月 30 日召开第八届董事会第 十九次临时会议，审议通过了《关于变更法定代表人的议案》。具体内容详见公司 在《中国证券报》《上海证券报》《证券日报》《证券时报》及上海证券交易所网站 www.sse.com.cn 披露的《第八届董事会第十六次会议决议公告》（公告编号：2025- 007）、《关于修改<公司章程>的公告》（公告编号 ...

Group 1 - The hair medical concept sector increased by 3.82%, ranking fifth among concept sectors, with 18 stocks rising, including Aoyang Health which hit the daily limit, and Tainkang, Jiuzhitang, and Kangyuan Pharmaceutical showing significant gains of 13.80%, 5.79%, and 5.73% respectively [1][2] - The hair medical concept sector attracted a net inflow of 132 million yuan from main funds today, with 10 stocks receiving net inflows, and 7 stocks seeing inflows exceeding 10 million yuan, led by Aoyang Health with a net inflow of 94.61 million yuan [2][3] - Aoyang Health, Nengte Technology, and Shuiyang Shares had the highest net inflow ratios, with 42.28%, 6.86%, and 6.82% respectively [3][4] Group 2 - The top stocks in the hair medical concept sector based on net inflow include Aoyang Health, Shuiyang Shares, and Langzi Shares, with respective net inflows of 94.61 million yuan, 53.93 million yuan, and 24.89 million yuan [2][3] - The trading performance of Aoyang Health showed a daily increase of 10.08% with a turnover rate of 7.13%, while other notable performers included Shuiyang Shares and Langzi Shares with increases of 4.22% and 3.10% respectively [3][4] - The overall market sentiment in the hair medical sector appears positive, as indicated by the significant inflows and stock performance [1][2]